Japan Builds Asia Links Through New AMED Programs
In line with similar initiatives by Japan on other regulatory fronts, the country's Agency for Medical Research and Development is building up its partnerships and presence in Asia.
You may also be interested in...
The International Council on Harmonisation has endorsed draft versions of two new guidelines – one on conducting multi-regional clinical trials and the other on supporting the non-clinical evaluation of anticancer medicines. The ICH is now seeking stakeholder feedback on both documents.
Pushed in part by host Japan, health issues including antimicrobial resistance and incentives for drug R&D in this and other sectors formed an important part of the agenda at last week's G7 meeting. But while there was plenty of recognition of important issues, concrete progress was limited.
An industry-led grouping of research-based pharma associations from across Asia has held its latest annual meeting in Tokyo at which it reported modest but steady progress across initiatives in the regulatory and drug discovery areas as it seeks to get novel medicines to patients faster.